• MetaBolon
• 14 Nov, 2018

Tumors are a continuously evolving ecosystem Tumors possess varying degrees of baseline heterogeneity and are prone to natural or drug-induced evolution leading to drug resistance. Thus, defining what to target to topple this ecosystem for clinical benefit is a daunting challenge. Tumors are also supported by a highly diverse ecosystem Although dominant drivers representing a key hallmark of cancer can be targeted and lead to efficacy and durable response.
Read more...